Exact Sciences Corporation

The Exact Sciences Corp First Quarter 2022 Earnings Call. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question and answer session. If you would like to ask a question during this time, please press star followed by the number one on your telephone keypad. If you would like to withdraw your question, again press star one. Thank you. Megan Jones, Senior Director of Investor Relations, you may begin your conference.

Thanks, Josh. Thank you for joining us for Exact Sciences' first quarter 2022 conference call. On the call today are Kevin Conroy, the company's chairman and CEO, and Jeff Elliott, our chief financial officer and chief operating officer. Everett Cunningham, our chief commercial officer, will also be available for questions. Exact Sciences issued a news release earlier this afternoon detailing our first quarter financial results. This news release and today's presentation are available on our website at exactsciences.com. During today's call, we will make forward-looking statements based on current expectations. Our actual results may have material differences from such statements. Reconciliations to gap figures are available in our earnings press release, and descriptions of the risks and uncertainties associated with Exact Sciences are included in our SEC filings. Both can be accessed through our website. I'll now turn the call over to Kevin.

The Exact Sciences' mission is to eradicate cancer by making earlier detection a routine part of medical care. The entire team at Exact Sciences helped us move towards achieving that mission with a strong start to 2022. Highlights from the first quarter include testing more than a million people globally, growing revenue 24%, excluding our COVID testing, partnering with Katie Couric on an exciting new campaign to get more people screened with Cologuard, Optimizing our sales force structure to reach primary care doctors more effectively and more efficiently. Guiding a record number of patients to more effective cancer treatments with Oncotype DX. Generating evidence to support our next generation Cologuard and multi-cancer early detection tests. Focusing intently on prioritization and growing our company efficiently. and beginning to integrate prevention genetics into our foundation. Jeff Elliott will now review our financial results.